Retatrutide vs Semaglutide: Dosage, Efficacy & Mechanism
A side-by-side, peer-reviewed comparison of Retatrutide and Semaglutide — mechanism, typical research dose and titration, clinical-trial efficacy, administration, and reconstitution. For research and educational purposes only.
| Attribute | Retatrutide | Semaglutide |
|---|---|---|
| Drug class | Weight Loss | Weight Loss |
| Mechanism of action | Retatrutide is a 39-amino-acid synthetic peptide with C20 fatty-acid acylation that drives albumin binding and yields a terminal half-life of approximately six days, enabling weekly subcutaneous administration . Unlike single-incretin agents, it engages… | Semaglutide is a 31-amino-acid synthetic analogue of human GLP-1 in which substitution at position 8 (alanine to α-aminoisobutyric acid) blocks DPP-4 enzymatic degradation and a C18 fatty-diacid linker at position 26 promotes reversible binding to serum… |
| Typical research dose | 2–8 mg once weekly (gradual escalation over 8–12 weeks). | 0.25–2.4 mg once weekly SC (16-week titration to 2.4 mg maintenance) |
| Headline trial efficacy | An exploratory analysis showed dose-dependent reductions in waist circumference of up to 17.8 cm at 48 weeks on 12 mg, paralleling the substantial visceral-fat loss seen on imaging . | Real-world cohort analyses confirm 10–13% average weight loss in clinical practice at 12 months, modestly below the STEP trial average — driven by lower titration completion rates and adherence. |
| Administration | Refer to guidelines | Refer to guidelines |
| Vial sizes | 5 mg, 10 mg, 20 mg, 30 mg | 5 mg, 10 mg, 20 mg |
| Storage | Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F) for up to 4 weeks[16]. | Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); use within 28 days; avoid repeated freeze–thaw cycles. |
Frequently Asked Questions
What is the difference between Retatrutide and Semaglutide?expand_more
Retatrutide (weight loss) and Semaglutide (weight loss) differ in receptor target and mechanism. Retatrutide is a 39-amino-acid synthetic peptide with C20 fatty-acid acylation that drives albumin binding and yields a terminal half-life of approximately six days, enabling weekly subcutaneous administration . Unlike single-incretin agents, it engages… By contrast, semaglutide: Semaglutide is a 31-amino-acid synthetic analogue of human GLP-1 in which substitution at position 8 (alanine to α-aminoisobutyric acid) blocks DPP-4 enzymatic degradation and a C18 fatty-diacid linker at position 26 promotes reversible binding to serum…
How do the typical research doses of Retatrutide and Semaglutide compare?expand_more
Retatrutide is typically dosed at 2–8 mg once weekly (gradual escalation over 8–12 weeks)., while Semaglutide is typically dosed at 0.25–2.4 mg once weekly SC (16-week titration to 2.4 mg maintenance). See each protocol for the full titration schedule.